| Abstrakt: |
Breast cancer patient who are on trastuzumab show higher plasma levels of biomarkers that are involved with cardiotoxicity that may limit the use of trastuzumab in breast cancer patients, atorvastatin and telmisartan are interesting agents that may ameliorate the trastuzumab - induced cardiotoxicity. In the present study, we examined the effects of pretreatment with atorvastatin and / or telmisartan on the trastuzumab - induced cardiotoxicity. This study, involved five groups; 10 male rats (administered normal saline), 10 rats (administered trastuzumab as positive control group), 10 rats (administered atorvastatin), 10 rats (administered telmisartan) and 10 rats (administered atorvastatin\telmisartan combination). Serum brain natriuretic peptide, cardiac troponin I, superoxide dismutase, and tumor necrosis factor were measured and heart histopathology was performed. The results were lower in pretreated groups when compared with trastuzumab group BNP, cTnI, SOD & TNF-a in trastuzumab group (17.17+1.94, 42.0±7.54, 1.933±0.74 & 37.333±8.96) respectively and all were significantly higher than those rats, which administered normal saline only. Combination group has shown significant improvement in trastuzumab - induced cardiotoxicity BNP, cTnI, SOD and TNF (14±1.41, 25.5±3.69, 1.275+0.28, 27.25±3.31) respectively, when compared with trastuzumab group. In conclusion, pretreatment with atorvastatin and / or telmisartan offered better protection from trastuzumab - induced cardiotoxicity than administering trastuzumab alone. [ABSTRACT FROM AUTHOR] |
